オプションチェーンは、MicroPort CardioFlowの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、MicroPort CardioFlowの市場センチメントを評価します。.

MicroPort CardioFlow (OTC:MROPF) 株価情報, オプションチェーン

MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.

MICROPORT CARDIOFLW MEDTH by MICROPORT CARDIOFLOW MEDTECH CORP.

MicroPort CardioFlow Medtech Corp

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Overweight and raises the price target from $492 to $510.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Domino's Pizza, Raises Price Target to $510

Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/V/earnings">closing bell on Tuesday, April 29</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.68 per share, up from $2.51 per share in the year-ago period. Visa projects to report quarterly revenue at $9.55 billion, compared to $8.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Visa has reportedly proposed a $100 million payment to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to secure the Apple Card network. This move comes amid fierce competition among the country's leading payment networks.
Visa shares gained 0.7% to close at $337.51 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/V/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Ramsey El-Assal maintained an Overweight rating and raised the price target from $361 to $396 on Feb. 3, 2025. This analyst has an accuracy rate of 65%.</li>
<li>BMO Capital analyst Rufus Hone maintained an Outperform rating and increased the price target from $350 to $370 on Jan. 31, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Mizuho analyst Dan Dolev maintained a Neutral rating and boosted the price target from $304 to $359 on Jan. 31, 2025. This analyst has an accuracy rate of 66%.</li>
<li>JP Morgan analyst Tien-Tsin Huang maintained an Overweight rating and increased the price target from $340 to $375 on Jan. 31, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Goldman Sachs analyst Matthew O'Neill maintained a Buy rating and raised the price target from $346 to $384 on Jan. 31, 2025. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png" alt="" class="wp-image-892185" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

AAPL

Top Wall Street Forecasters Revamp Visa Expectations Ahead Of Q2 Earnings

Buybacks

RVSB

Riverview Bancorp Board Adopts Repurchase Program Up To $2M

JP Morgan analyst Tien-Tsin Huang maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Neutral and lowers the price target from $92 to $81.

CTSH

JP Morgan Maintains Neutral on Cognizant Tech Solns, Lowers Price Target to $81

<ul>
<li>Orchestra BioMed's Virtue&#xAE; Sirolimus AngioInfusion Balloon&#x2122;("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations</li>
<li>The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT&#x2122;) for the treatment of coronary in-stent restenosis ("ISR")</li>
<li>Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB</li>
<li>With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025</li>
</ul>
NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration ("FDA") has approved its Investigational Device Exemption ("IDE") amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial ("Virtue Trial"). The IDE provides FDA regulatory clearance for Orchestra BioMed to initiate a U.S. pivotal clinical trial comparing its highly differentiated, next-generation Sirolimus-AngioInfusion Balloon, Virtue SAB to the Boston Scientific AGENT paclitaxel-coated balloon, currently the only drug-coated balloon ("DCB") FDA-approved for a coronary indication. Data from the Virtue Trial will be used to support regulatory approval in the U.S. Virtue SAB and SirolimusEFR are investigational technologies owned by Orchestra BioMed, which also controls and is responsible for all regulatory filings, clinical operations, and drug and device supplies for the Virtue Trial.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Holdings: FDA Approves IDE Amendment To Initiate Updated Design Of Virtue SAB In Treatment Of Coronary ISR Trial

In the preceding three months, 9 analysts have released ratings for Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.94, a high estimate of $5.00, and a low estimate of $2.00. Highlighting a 25.38% decrease, the current average has fallen from the previous average price target of $3.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931752_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Traeger by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $3.00&#x7C;$5.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $2.50&#x7C;$2.50 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $2.50&#x7C;$3.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $2.00&#x7C;$2.75 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.75 &#x7C; 
&#x7C;Peter Benedict &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.50 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $5.00&#x7C;$7.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $2.50&#x7C;$4.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $4.00&#x7C;$4.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Traeger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Traeger compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Traeger's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COOK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Traeger analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Traeger</h2>
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
<h3>Breaking Down Traeger's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Traeger's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.16%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -4.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Traeger's ROE excels beyond industry benchmarks, reaching -2.5%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Traeger's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Traeger's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COOK

Expert Outlook: Traeger Through The Eyes Of 9 Analysts

During the last three months, 9 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.89, a high estimate of $57.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 0.36% increase from the previous average price target of $38.75.
<img src="https://www.benzinga.com/files/images/story/2025/1745931741_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Apellis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eliana Merle &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $21.00&#x7C;$24.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $31.00&#x7C;$30.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $25.00&#x7C;$26.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $32.00&#x7C;$36.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apellis Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Apellis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Breaking Down Apellis Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.19% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -17.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 2.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals

During the last three months, 12 analysts shared their evaluations of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $65.0, a high estimate of $72.00, and a low estimate of $56.00. Witnessing a positive shift, the current average has risen by 4.0% from the previous average price target of $62.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745931734_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Molson Coors Beverage among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $61.00&#x7C;$62.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $62.00&#x7C;$56.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Underweight &#x7C; $56.00&#x7C;$48.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $63.00&#x7C;$58.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Dara Mohsenian &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $63.00&#x7C;$60.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Filippo Falorni &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $57.00&#x7C;$47.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $58.00&#x7C;$59.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molson Coors Beverage. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Molson Coors Beverage compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Molson Coors Beverage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Molson Coors Beverage's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molson Coors Beverage analyst ratings.</a>
<h2>Delving into Molson Coors Beverage's Background</h2>
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
<h3>A Deep Dive into Molson Coors Beverage's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Molson Coors Beverage's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.98%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Molson Coors Beverage's net margin excels beyond industry benchmarks, reaching 10.52%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Molson Coors Beverage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.18%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Molson Coors Beverage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.09%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Molson Coors Beverage's debt-to-equity ratio is below the industry average at 0.47, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Molson Coors Beverage Stands With Analysts

Ross Stores's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NYSE">ROST</a>) short percent of float has risen 27.01% since its last report. The company recently reported that it has 7.12 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ross Stores Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931728_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ross Stores has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ross Stores's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ross Stores's peer group average for short interest as a percentage of float is 14.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ROST

What's Driving the Market Sentiment Around Ross Stores?

During the last three months, 16 analysts shared their evaluations of Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">11</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.81, with a high estimate of $31.00 and a low estimate of $14.00. A 16.76% drop is evident in the current average compared to the previous average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931726_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Avantor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$23.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $20.00&#x7C;$24.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $14.00&#x7C;$26.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $15.00&#x7C;$18.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $15.00&#x7C;$25.00 &#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $17.00&#x7C;$21.00 &#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $22.00&#x7C;$25.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $18.00&#x7C;$23.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$22.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $26.00&#x7C;$28.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $24.00&#x7C;$26.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $31.00&#x7C;$33.00 &#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $25.00&#x7C;$28.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $23.00&#x7C;$26.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $26.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avantor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avantor compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Avantor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Avantor's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AVTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avantor analyst ratings.</a>
<h2>About Avantor</h2>
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education &amp; government, and advanced technologies &amp; applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment &amp; instrumentation, Services &amp; specialty procurement, Proprietary materials &amp; consumables, and Third-party materials &amp; consumables. Materials &amp; consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
<h3>Unraveling the Financial Story of Avantor</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Avantor's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -5.86%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avantor's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Avantor's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.07% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Avantor's ROA excels beyond industry benchmarks, reaching 0.53%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVTR

Demystifying Avantor: Insights From 16 Analyst Reviews

WIIM

PYPL

PYPL stock has given up its prior loss. PayPal shares were trading lower following a Q1 revenue miss.

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 25.73% since its last report. The company recently reported that it has 18.23 million shares sold short, which is 9.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 6.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

EXEL

Is the Market Bullish or Bearish on Exelixis?

Ratings for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $188.62, along with a high estimate of $250.00 and a low estimate of $145.00. A decline of 7.93% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931719_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Qualcomm by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Samik Chatterjee &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $185.00&#x7C;- &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $145.00&#x7C;$185.00 &#x7C; 
&#x7C;Joshua Buchalter &#x7C;TD Cowen &#x7C;Lowers &#x7C;Buy &#x7C; $160.00&#x7C;$195.00 &#x7C; 
&#x7C;Cody Acree &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Mark Lipacis &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $179.00&#x7C;$199.00 &#x7C; 
&#x7C;Matthew Prisco &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $160.00&#x7C;$160.00 &#x7C; 
&#x7C;Harsh Kumar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $190.00&#x7C;$205.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $250.00&#x7C;$250.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Qualcomm. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Qualcomm compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Qualcomm's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Qualcomm's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Qualcomm analyst ratings.</a>
<h2>Discovering Qualcomm: A Closer Look</h2>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Financial Insights: Qualcomm</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Qualcomm displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 17.45%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Qualcomm's net margin is impressive, surpassing industry averages. With a net margin of 27.25%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Qualcomm's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Qualcomm's ROA excels beyond industry benchmarks, reaching 5.74%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.54, Qualcomm faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

QCOM

Beyond The Numbers: 8 Analysts Discuss Qualcomm Stock

RB Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) short percent of float has risen 8.13% since its last report. The company recently reported that it has 5.11 million shares sold short, which is 3.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>RB Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RB Global has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing RB Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, RB Global's peer group average for short interest as a percentage of float is 6.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into RB Global's Recent Short Interest

7 analysts have shared their evaluations of Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $324.57, a high estimate of $355.00, and a low estimate of $293.00. Marking an increase of 11.73%, the current average surpasses the previous average price target of $290.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931711_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Insulet by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Announces &#x7C;Outperform &#x7C; $340.00&#x7C;- &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $355.00&#x7C;$310.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $328.00&#x7C;$294.00 &#x7C; 
&#x7C;Mathew Blackman &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $293.00&#x7C;$245.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $310.00&#x7C;$285.00 &#x7C; 
&#x7C;Lawrence Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $322.00&#x7C;$305.00 &#x7C; 
&#x7C;Kyle Rose &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $324.00&#x7C;$304.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Insulet's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Insulet's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
<h3>Insulet's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Insulet displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 17.2%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE stands out, surpassing industry averages. With an impressive ROE of 8.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Insulet's ROA stands out, surpassing industry averages. With an impressive ROA of 3.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.15, Insulet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PODD

The Analyst Verdict: Insulet In The Eyes Of 7 Experts

JP Morgan analyst Kenneth Worthington maintains Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) with a Neutral and lowers the price target from $69 to $62.

VCTR

JP Morgan Maintains Neutral on Victory Capital Holdings, Lowers Price Target to $62

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) with a Overweight rating and announces Price Target of $28.

Initiation

PHVS

Cantor Fitzgerald Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $28

Morgan Stanley analyst Joseph Moore maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Equal-Weight and lowers the price target from $24 to $19.

AMKR

Morgan Stanley Maintains Equal-Weight on Amkor Tech, Lowers Price Target to $19

TER stock has given up its prior gain. Teradyne shares were trading higher after the company reported better-than-expected Q1 financial results.

United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) shares rose in premarket trading Tuesday after the company posted better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45061148/ups-releases-1q-2025-earnings" rel="noreferrer noopener">first-quarter 2025 results</a>.
UPS reported a consolidated revenue decline of 0.7% year-over-year to $21.546 billion, beating the consensus of $21.05 billion. Adjusted EPS was $1.49, up 4.3% YoY, above the consensus of $1.38.
GAAP results included a net charge of $83M ($0.09/share) tied to strategy costs and asset impairments, partially offset by a small tax benefit reversal.
The company consolidated operating profit of $1.763 billion, up 3.3% year over year. Adjusted operating profit rose 0.9%. Adjusted operating margin stood at 8.2%, up from 8.00% a year ago.
U.S. Domestic Segment revenue increased 1.4% to $14.46 billion, reflecting a 4.5% increase in revenue per piece and increases in air cargo. The adjusted operating margin stood at 7%.
International Segment revenue grew 2.7% to $4.373 billion, reflecting a 7.1% increase in average daily volume. The adjusted operating margin was 15%.
Supply Chain Solutions Segment revenue declined by 14.8% to $2.713 billion, driven by the Coyote divestiture. The adjusted operating margin was 3.6%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44696476/ups-expands-delivery-options-with-two-new-ground-services" rel="noreferrer noopener">UPS Expands Delivery Options With Two New Ground Services</a>
UPS' operating cash flow for the quarter totaled $2.318 billion, and free cash flow was $1.487 billion.
"As a trusted leader in global logistics, we will leverage our integrated network and trade expertise to assist our customers as they adapt to a changing trade environment. Further, the actions we are taking to reconfigure our network and reduce cost across our business could not be timelier. The macro environment may be uncertain, but with our actions, we will emerge as an even stronger, more nimble UPS," said Carol Tomé, UPS&#8217;s chief executive officer.
2025 Outlook: Amid ongoing macroeconomic uncertainty, UPS is holding off on updating its full-year outlook and will share Q2 expectations during its Q1 2025 earnings call.
Previous guidance: UPS expects revenue of ~ $89 billion, below the $95.01 billion consensus, and sees an adjusted operating margin of 10.8%.
The company plans $3.5 billion in capital spending, $5.5 billion in dividends (pending approval), $1 billion in share buybacks, and an expected 23.5% tax rate.
Price Action: UPS shares are trading higher by 0.95% at $98.01 premarket at the last check Tuesday.
Photo: Shutterstock

Comments

MicroPort CardioFlow

MicroPort CardioFlow (MROPF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル